Suggested remit: To appraise the clinical and cost effectiveness of daridorexant within its marketing authorisation for treating insomnia.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3774

Provisional Schedule

Expected publication 16 August 2023

Project Team

Project lead Daniel Davies

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
25 April 2022 Invitation to participate
18 April 2022 As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Daridorexant for treating insomnia [ID3774]. Please note that following conversations between NICE and the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late April 2022 when we will write to you about how you can get involved.
27 January 2022 Please note that following on from a request received from the company, the timelines for this appraisal have been revised slightly and the appraisal is now anticipated to begin in mid-February 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
27 October 2021 (14:00) Scoping workshop
09 September 2021 - 07 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual